Portfolio companies news

13 February 2014

Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration (FDA) has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

13 February 2014

Syndax Announces NCI And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer

Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer. 

12 February 2014

Regado Biosciences, Inc., Broadens Patent Family Protecting Core Technology

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Patent and Trademark Office (USPTO) has issued an important patent that expands protection of Regado's core technology platform while broadening the range of aptamer-based therapies upon which Regado may base future products.

12 February 2014

Miramar Labs Secures $10 Million in Series D Funding

Miramar Labs®, Inc., a leading medical device manufacturer and maker of the miraDry® System, announced today it has raised $10 million in Series D funding from Aisling Capital, Cross Creek Capital, Domain Associates, Morgenthaler Ventures, and RusnanoMedInvest. The new investment will be used to expand sales activities around the world, support commercialization efforts in Europe given the recent CE Mark approval and support R&D efforts on products for new indications.

11 February 2014

Lithera Announces Final Closing of $35.6 Million Series C Financing

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that it has completed the final closing of its Series C preferred stock equity financing, securing an additional $8.0 million in equity capital and bringing the total capital raised in this round to $35.6 million. 

03 February 2014

Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center.

31 January 2014

Regado Biosciences Announces $20 Million Private Placement

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it has entered into a definitive agreement to sell $20 million of its common stock in a private placement to new and existing investors. Under the agreement, the investors will purchase an aggregate of 4 million shares of common stock at a purchase price of $5.00 per share. 

29 January 2014

Regado Biosciences, Inc., Demonstrates Safety of Early Sheath Removal in Patients Treated with REG1 in Phase 2b Study

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the publication of additional findings from its completed Phase 2b RADAR trial in the Journal of Invasive Cardiology¹ demonstrating the safety of early sheath removal in patients treated with REG1.

23 January 2014

Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions.

13 January 2014

Marinus Pharmaceuticals Bolsters Its Board of Directors and Executive Management

Elects Two Life Sciences Veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to Its Board of Directors; Appoints Edward F. Smith as Chief Financial Officer.